Xenon Pharmaceuticals Inc. — Q2 2020 Form 10-Q
Reporting period: Three and six months ended June 30, 2020. Amounts below are in U.S. dollars; financial statement figures are rounded to millions unless stated otherwise.
Business context
Xenon is a clinical-stage biopharmaceutical company developing therapies for neurological disorders, particularly epilepsy. It has no significant product-sales revenue; reported revenue was from its Neurocrine Biosciences collaboration. The interim statements are unaudited.
Key financial metrics
| Metric | Q2 2020 | Six months 2020 | Comparable 2019 period |
|---|---|---|---|
| Revenue | $13.384 million | $20.462 million | $0 |
| Research and development expense | $10.720 million | $22.511 million | $8.205 million / $17.342 million |
| General and administrative expense | $3.310 million | $6.630 million | $2.307 million / $4.928 million |
| Operating loss | $0.646 million | $8.679 million | $10.512 million / $22.270 million |
| Net loss | $0.175 million | $7.659 million | $10.007 million / $21.348 million |
| Net loss per common share | $0.00 | $0.22 | $0.37 / $0.80 |
Q2 operating margin was approximately negative 4.8% on collaboration revenue; product gross margin is not applicable because the company reported no product sales. Q2 results included a $0.988 million loss on early repayment of the term loan, offset in part by interest income and foreign-exchange gains.
At June 30, cash and cash equivalents were $44.199 million and marketable securities were $158.555 million, totaling $202.754 million. Total assets were $210.676 million; shareholders’ equity was $189.298 million. The $15.5 million term loan was repaid in May, leaving no term-loan balance at quarter-end. Six-month operating cash use was $23.856 million; investing cash use was $41.991 million and financing cash provided was $85.750 million. The financing included $102.456 million of net common-share issuance proceeds, partly offset by loan repayment.
Changes versus prior comparable periods
- Revenue rose from zero in 2019, reflecting recognition of Neurocrine collaboration consideration and research and development services.
- Six-month net loss narrowed to $7.659 million from $21.348 million, despite higher R&D and G&A spending, largely because collaboration revenue was recognized.
- R&D expense increased by $5.169 million for the first half, primarily due to higher XEN1101 and XEN496 spending; lower XEN901-related spending partly offset the increase.
- Cash and marketable securities increased from $141.358 million at year-end 2019 to $202.754 million at June 30, 2020, supported by equity issuance. The company also eliminated its term-loan debt.
Outlook, commentary and risks
- Management expects significant expenses and operating losses for the foreseeable future, including the next 12 to 24 months. It stated that cash, cash equivalents and marketable securities were expected to fund operating and capital needs for at least 12 months, while noting that assumptions could prove wrong.
- XEN1101’s Phase 2b X-TOLE trial was ongoing; COVID-19 reduced enrollment rates. Topline data were anticipated in the first half of 2021, dependent on enrollment. XEN007 study results were also pushed to the first half of 2021 after an investigator site closed for several months.
- XEN496 Phase 3 initiation was anticipated in 2020, subject to FDA protocol review and the ability to open sites and enroll patients. Neurocrine anticipated an IND filing for NBI-921352 in the near term and a Phase 2 trial in the second half of 2020; Xenon could receive up to $25 million upon FDA acceptance of the IND, subject to agreement terms.
- COVID-19 risks include continued clinical enrollment and timeline disruption, reduced laboratory activity, supply-chain issues, and uncertainty around financing markets. Management reported no material COVID-19 financial-statement impact through June 30, but said future effects were uncertain.
- The Neurocrine agreement generated $13.384 million of Q2 revenue and left $12.692 million of deferred revenue at quarter-end. Revenue recognition includes license-related consideration and services; it is not evidence of product sales or recurring commercial revenue.
- After quarter-end, Xenon entered an ATM sales agreement for up to $100 million of common shares. It also amended the XEN1101 asset purchase agreement with 1st Order: potential future milestones include up to $1.2 million clinical, $6.0 million regulatory and $0.5 million other payments; $0.3 million was accrued.
- Key risks include clinical and regulatory failure or delay, dependence on collaborators and third-party manufacturers, future financing needs and potential dilution, foreign-exchange exposure, and uncertainty in small patient populations. The filing reports no material legal proceedings and no material changes to internal control over financial reporting; disclosure controls were assessed as effective at a reasonable-assurance level.
Important facts for investors to verify
- Progress and enrollment in the X-TOLE trial, and whether COVID-19 changes the anticipated first-half 2021 topline timing.
- FDA feedback and actual start and enrollment of the XEN496 Phase 3 trial; Neurocrine’s NBI-921352 IND, trial progress and milestone conditions.
- Cash burn, investment liquidity and the assumptions behind management’s at-least-12-month funding assessment.
- Future revenue recognition and deferred-revenue runoff under the Neurocrine agreement; milestone receipts remain contingent and uncertain.
- Use of the post-quarter $100 million ATM authority, potential share dilution, and contingent XEN1101 milestone obligations.